Ken Griffin Aadi Bioscience, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Aadi Bioscience, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 15,000 shares of AADI stock, worth $38,850. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,000
Previous 23,800
36.97%
Holding current value
$38,850
Previous $49,000
4.08%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding AADI
# of Institutions
57Shares Held
15.5MCall Options Held
23.8KPut Options Held
0-
Avoro Capital Advisors LLC New York, NY2.85MShares$7.38 Million0.13% of portfolio
-
Qvt Financial LP New York, NY2.31MShares$5.99 Million0.72% of portfolio
-
Bml Capital Management, LLC Zionsville, IN2.1MShares$5.44 Million4.12% of portfolio
-
Acuta Capital Partners, LLC Belmont, CA1.85MShares$4.79 Million8.31% of portfolio
-
Acorn Capital Advisors, LLC New York, NY1.15MShares$2.97 Million1.96% of portfolio
About Aadi Bioscience, Inc.
- Ticker AADI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 21,016,800
- Market Cap $54.4M
- Description
- Aadi Bioscience, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug candidate, FYARRO is a form of sirolimus bound to albumin. Aadi is evaluating FYARRO in cancers with known mTOR pathway activation, ...